Iris Detrez
YOU?
Author Swipe
View article: A Population Pharmacokinetic and Exposure–Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis
A Population Pharmacokinetic and Exposure–Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis Open
Background Unlike other anti–tumor necrosis factor alpha antibodies, golimumab does not deliver on its promise of effectiveness for treating patients with ulcerative colitis. We investigated the value of therapeutic drug monitoring for opt…
View article: P589 A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis
P589 A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis Open
From the PURSUIT programme, it is known that golimumab (GLM) trough concentrations (TC) >2.5 mg/l at week (w)6 of induction therapy are associated with clinical response in patients with ulcerative colitis (UC).1 No TC threshold has been e…
View article: P431 Golimumab dried blood spot analysis (GOUDA): A prospective trial to validate golimumab concentration analysis using the dried blood spot methodology
P431 Golimumab dried blood spot analysis (GOUDA): A prospective trial to validate golimumab concentration analysis using the dried blood spot methodology Open
Therapeutic drug monitoring of golimumab (GLM) is performed by measuring trough concentrations, obtained by venous sampling. Sampling via dried blood spots (DBS) allows multiple determinations within a dosing interval and thereby gives a m…
View article: P484 Infliximab and vedolizumab show a different effect on clot formation in inflammatory bowel disease patients
P484 Infliximab and vedolizumab show a different effect on clot formation in inflammatory bowel disease patients Open
Inflammation and thrombosis are intertwined. Therefore, ulcerative colitis (UC) and Crohn’s disease (CD) patients tend to have an altered clot-lysis (CL) profile, which may reflect their higher risk for venous thromboembolic events (VTE). …
View article: P632 Trough levels of golimumab at Week 6 predict drug retention rate in ulcerative colitis
P632 Trough levels of golimumab at Week 6 predict drug retention rate in ulcerative colitis Open
Real-life data on clinical efficacy and pharmacokinetics of golimumab in ulcerative colitis are scarce. We aimed to study clinical outcome and pharmacokinetics of golimumab in real-life settings and to identify biochemical and clinical pre…
View article: Immunoassay for Detection of Infliximab in Whole Blood Using a Fiber-Optic Surface Plasmon Resonance Biosensor
Immunoassay for Detection of Infliximab in Whole Blood Using a Fiber-Optic Surface Plasmon Resonance Biosensor Open
Monitoring the concentration of a therapeutic drug antibody, infliximab (IFX), is recommended for enhancing its efficacy in patients with inflammatory bowel disease (IBD). However, IFX concentrations are currently determined in patients' s…
View article: P686 Application of dried blood spots for pharmacokinetic profiling of golimumab-treated patients with ulcerative colitis
P686 Application of dried blood spots for pharmacokinetic profiling of golimumab-treated patients with ulcerative colitis Open
Background: Preventing loss of response to golimumab, an anti-tumour necrosis factor (TNF) biologic, is a challenge for clinicians treating patients with ulcerative colitis (UC). Although drug serum concentrations and anti-drug antibody se…
View article: P226 Comparison of four different immunoassays for measuring golimumab and anti-golimumab antibody concentration in patients with ulcerative colitis
P226 Comparison of four different immunoassays for measuring golimumab and anti-golimumab antibody concentration in patients with ulcerative colitis Open
Background: Golimumab is an anti-TNF antibody with higher affinity for TNF compared to infliximab and adalimumab and higher stability compared to infliximab1. The PURSUIT trials showed a significant exposure-response relationship with goli…
View article: Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies Open
Although tumour necrosis factor-α [TNF] antagonists have revolutionized therapy for ulcerative colitis [UC], challenges still remain. Even today a significant proportion of patients fail induction therapy [primary non-responders] and many …
View article: Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis
Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis Open
Adequate exposure to golimumab drives clinical response. A worse disease at baseline influences clinical response rate negatively.